5 Best Stocks To Watch For 2015: Luna Innovations Incorporated(LUNA)
Luna Innovations Incorporated engages in the research, development, and commercialization of technologies in the areas of sensing and instrumentation products, and health care products primarily in the United States. The company?s Product and Licensing segment offers test and measurement products to monitor the integrity of fiber optic network and sub-assemblies. This segment provides Optical Vector Analyzer platform, a device for single-measurement, all-parameter analysis of fiber optic components and assemblies up to 150 meters in length; Optical Backscatter Reflectometer, a sensitive diagnostic device, for data and telecommunications companies, and service providers who maintain their own fiber optic networks; and Phoenix laser, a MEMs-based external cavity laser, that offers low noise and precise tuning capability over the C-band. It also offers distributed sensing systems, which comprise multiple sensors whose input is integrated through a fiber optic network and soft ware to detect distributed strain, shape, and temperature; and tunable lasers. In addition, this segment provides health care products, including medical devices for minimally invasive diagnostics, surgery, and therapy; non-invasive monitoring and diagnosis medical devices consisting of emboli detection and classification QUANTIFIER, a non-invasive medical device, that uses quantitative ultrasound technology to count emboli in ex-vivo blood circuit; and nanomaterial-based medical products comprising Trimetasphere nanomaterials. The company?s Technology Development segment provides contract research services to universities, government entities, and corporations. Luna Innovations Incorporated offers its services to energy, telecommunications, life sciences, and defense industries .The company was incorporated in 1990 and is headquartered in Roanoke, Virginia.
Advisors' Opinion:- [By John Udovich]
Yesterday, Luna Innovations Incorporated (NASDAQ: LUNA), a rather unusual and innovative small cap stock,�soared some 23.26%���meaning its worth taking a closer look at the stock along with its performance verses the performance of small cap benchmarks like the iShares Russell 2000 Index ETF (NYSEARCA: IWM), the�iShares Russell 2000 Value Index ETF (NYSEARCA: IWN) or the iShares Russell 2000 Growth Index ETF (NYSEARCA: IWO).
- [By Monica Gerson]
Luna Innovations (NASDAQ: LUNA) jumped 95.45% to $2.58 as the company announced its plans to sell its shape-sensing technology to Intuitive Surgical (NASDAQ: ISRG).
Top Penny Stocks To Own Right Now: Theravance Inc.(THRX)
Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines for various therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The company?s key development programs with GlaxoSmithKline (GSK) include the RELOVAIR, a Phase 3 clinical trial program for the treatment of patients with chronic obstructive pulmonary disease (COPD) and/or asthma; the LAMA/LABA program, a Phase 3 COPD program; and the Bifunctional Muscarinic Antagonist-beta2 Agonist (MABA) program, a Phase 2b program for the treatment of COPD, as well as Peripherally Selective Mu-Opioid Receptor Antagonist (P Advisors' Opinion:
- [By Sean Williams]
Things are about to getting very exciting for existing shareholders of biopharmaceutical company Theravance (NASDAQ: THRX ) , with the company announcing its first-quarter results after the closing bell and setting a record date of May 15 for its split into two separate trading entities.
- [By Jonas Elmerraji]
First up is $4 billion biopharmaceutical firm Theravance (THRX). It's been one heck of a year already for THRX's shareholders. Since the calendar flipped over to January, shares of the firm have rallied more than 75%. But the setup forming in shares points to even higher ground for the final quarter of 2013.
That's because Theravance is currently forming an ascending triangle pattern, a bullish setup that's formed by a horizontal resistance level above shares at $42 and uptrending support to the downside. Basically, as Theravance bounces in between those two technical levels, it's getting squeezed closer and closer to a breakout above that $42 resistance level. When that happens, traders have a buy signal.
Whenever you're looking at any technical price pattern, it's critical to think in terms of those buyers and sellers. Ascending triangles and other pattern names are a good quick way to explain what's going on in a stock, but they're not the reason it's tradable. Instead, it all comes down to supply and demand for shares.
That $42 is a price where there has been an excess of supply of shares; in other words, it's a place where sellers have been more eager to step in and take gains than buyers have been to buy. That's what makes a breakout above it so significant -- the move means that buyers are finally strong enough to absorb all of the excess supply above that price level.
Don't be early on this trade.
- [By Sean Williams]
Perhaps the most exciting new treatment to hit the market in years was recently approved by the FDA. Developed by GlaxoSmithKline (NYSE: GSK ) and Theravance (NASDAQ: THRX ) , Breo Ellipta is a dry powder drug delivered by inhaler and meant to provide long-term relief of air-flow obstruction and reduce COPD exacerbations. The two companies are collaborating on a handful of potentially revolutionary new COPD treatments that combine Theravance's long-acting beta-2 agonists with Glaxo's long-acting muscarinic antagonists. Its next treatment, Breo Anoro, is currently under review by the FDA.
- [By Sean Williams]
Finally, Theravance (NASDAQ: THRX ) made waves after announcing that it would be splitting its business into two separate components: Royalty Management, which will focus on drugs currently in the pipeline in collaboration with GlaxoSmithKline, and Theravance BioPharma, which will continue its line of small-molecule rare disease research. Clearly, this gives investors more visibility of where revenue and profit are coming from, but I think it gives Glaxo even more reason to gobble up the Royalty Management segment because now it doesn't have to buy the remaining pipeline of rare disease research.
Top Penny Stocks To Own Right Now: China Nepstar Chain Drugstore Ltd (NPD)
China Nepstar Chain Drugstore Ltd. operates retail drugstores in the People?s Republic of China. The company?s drugstores provide pharmacy services and other merchandise, including prescription drugs; over-the-counter drugs; nutritional supplements, such as healthcare supplements, vitamins, minerals, and dietary products; herbal products, including drinkable herbal remedies and packages of assorted herbs for making soup; and private label products. Its stores also offer personal care products, such as skin care, hair care, and beauty products; family care products, including portable medical devices for family use, birth control products, and early pregnancy test products; and convenience products, such as soft drinks, packaged snacks, other consumables, cleaning agents, and stationeries, as well as seasonal and promotional items. The company operates its stores under the China Nepstar brand name. As of December 31, 2009, its store network comprised 2,479 retail drugstores located in approximately 71 cities in Guangdong, Jiangsu, Zhejiang, Liaoning, Shandong, Hunan, Fujian, Sichuan, and Hubei provinces, as well as in Shanghai, Tianjin, and Beijing municipalities of the People?s Republic of China. The company was founded in 1995 and is headquartered in Shenzhen, the People?s Republic of China.
Advisors' Opinion:- [By Garrett Cook]
Non-cyclical consumer goods & services shares dropped around 0.20 percent in today’s trading. Top decliners in the sector included K12 (NYSE: LRN), China Nepstar Chain Drugstore (NYSE: NPD), and Du Pont (NYSE: DD).
Top Penny Stocks To Own Right Now: Lexington Realty Trust (LXP)
Lexington Corporate Properties Trust operates as a self-managed and self-administered real estate investment trust (REIT). The company acquires, owns, and manages a portfolio of office, industrial, and retail properties net-leased to corporate tenants in the United States. It also provides investment advisory and asset management services to institutional investors in the net lease area. As of June 30, 2005, the company operated 185 properties and managed 2 properties. Lexington Corporate Properties Trust has elected to qualify as a REIT for federal income tax purposes. As a REIT, it would not be taxed on the portion of its income, which is distributed to shareholders, provided it distributes at least 90% of its taxable income. The company was founded in 1991 and is based in New York City.
Advisors' Opinion:- [By CRWE]
Lexington Realty Trust (NYSE:LXP), a real estate investment trust (REIT) focused on single-tenant real estate investments, reported that it would release its third quarter 2012 results the morning of Tuesday, November 6, 2012. Lexington will conduct a teleconference that same day at 11:00 a.m., Eastern Time.
No comments:
Post a Comment